Press Releases

Found 261 Results
Page 2 of 27

Summary of Onxeo’s Liquidity Contract with Kepler Cheuvreux


July 3, 2020 – 6:00 pm CEST   Pursuant to the liquidity contract granted to Kepler Cheuvreux regarding Onxeo shares, […]

Tags:

07/03/2020


Onxeo Confirms in Preclinical Studies the Profile of OX401, a Potent PARP Agonist with Strong Anti-Tumor Activity and Immunological Properties


Paris (France), June 25, 2020 – 7.00 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

06/25/2020


New AsiDNA™ e-Poster Now Online at AACR Virtual Meeting 2020


Preclinical Data Confirm the Ability of AsiDNA™ to Reverse Cancer Resistance to PARPi by Preventing Regrowth of Death-Tolerant Cells   […]

Tags:

06/22/2020


Onxeo: report on the Extraordinary General Meeting of June 19, 2020


Paris (France), June 19, 2020 – 5.45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the […]

Tags:

06/19/2020



Onxeo offre 10,7% de son capital à Invus – Biotech Finances


(French only) Regards croisés : Interviews of Judith Greciet, CEO of Onxeo, and Mr Nicolas Trebouta, representing Financière de la […]

Tags:

06/15/2020


BFM Business Intégrale Bourse : Onxeo, Company of the Day


  Interview of Judith Greciet, CEO of Onxeo, following the entry into the capital of Invus, a long-term renowned investor […]

Tags: ,

06/10/2020


Onxeo announces a capital increase of €7.3 million by private placement to Invus and Financière de la Montagne, the Company’s historical shareholder


The funds raised will accelerate the development of Onxeo’s programs, and extend its cash runway into Q1 2022                 Paris […]

Tags:

06/09/2020


Onxeo announces that the Shareholders’ Meeting of May 29, 2020 has approved all ordinary resolutions


The Extraordinary General Meeting will be held on June 19, 2020 on the second call   Paris (France), May 29, […]

Tags:

05/29/2020


Onxeo Announces Approval of the REVocan Study By Regulatory Authorities


The REVocan study aims to evaluate the abrogation by AsiDNA™ of tumor resistance to a PARP inhibitor in relapsed ovarian […]

Tags:


Page 2 of 27